Saturday 17 October 2026
Export ALLR’s income statement to Excel — free account
Allarity Therapeutics, Inc.
ALLR Healthcare Biotechnology
Allarity Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $320,000.00. In the quarter to June 2026, EPS fell 40.0%, free cash flow grew 53.2% and total debt rose 3.56%, each against the same quarter a year earlier.
0.90
0.07
+8.43%
Follow ALLR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(122.61%) | (103.80%) | (87.92%) | (157.09%) | |
| (74.37%) | (54.91%) | (34.80%) | (46.26%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(127.47%) | (114.28%) | (162.56%) | (348.81%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.00) | (1.05) | (1.07) | (0.88) | |
Free Cash Flow |
(14.78) | (15.15) | (17.01) | (14.08) | |
Capital Expenditures |
— | (0.33) | (0.39) | (0.37) | |
| Other line items | |||||
Cash ROIC |
(48.80%) | (58.45%) | (44.60%) | (44.08%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(84.60) | (68.14) | (34.33) | (10.15) | |
Operating CF/Net income |
0.97 | 1.32 | 1.48 | 1.11 | |
Depreciation/Fixed assets |
(0.06) | (0.04) | (0.12) | (0.07) | |
Capex/Depreciation |
0.00 | 25.15 | 7.76 | 13.21 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.00) | (1.03) | (1.04) | (0.86) | |
Capex per Share |
0.00 | (0.02) | (0.02) | (0.02) | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates